MenaquinGold (Vitamin K2 MK-7)

MenaquinGold is a branded, fermentation-derived form of menaquinone-7 (MK-7), the long-chain vitamin K2 subtype extracted from chickpea-fermented Bacillus subtilis natto cultures. MK-7 activates matrix Gla protein (MGP) and osteocalcin through gamma-carboxylation, directing calcium into bone tissue and away from arterial walls.

Origin & History

MenaquinGold is a branded form of menaquinone-7 (MK-7), a subtype of vitamin K2 characterized by a naphthoquinone ring with a seven-isoprenyl side chain. It is produced via microbial fermentation using Bacillus subtilis, with extraction through thermo-acidic hydrolysis or solvent methods, followed by HPLC purification.

Historical & Cultural Context

No historical or traditional medicine context is mentioned in the research. The available information focuses solely on modern microbial fermentation and chemical production methods rather than ethnomedical origins.

Health Benefits

• No clinical health benefits documented - research focuses only on production methods
• No efficacy data available - studies limited to extraction techniques
• No health outcome trials found - evidence restricted to analytical methods
• No therapeutic effects studied - research addresses only synthesis processes
• No biomedical applications reported - literature covers manufacturing only

How It Works

MK-7 serves as a cofactor for gamma-glutamyl carboxylase, the enzyme that carboxylates glutamic acid residues on vitamin K-dependent proteins including osteocalcin and matrix Gla protein (MGP). Carboxylated osteocalcin binds hydroxyapatite in bone matrix, promoting mineralization, while carboxylated MGP inhibits vascular calcification by chelating calcium ions and bone morphogenetic protein-2 (BMP-2) in arterial smooth muscle. MenaquinGold's all-trans MK-7 configuration confers a plasma half-life of approximately 72 hours, enabling once-daily dosing and sustained tissue saturation compared to shorter-chain MK-4.

Scientific Research

No human clinical trials, RCTs, or meta-analyses for MenaquinGold or MK-7 were found in the research. The available literature focuses exclusively on production, extraction, purification, and analytical methods rather than efficacy or health outcomes. No PubMed PMIDs for clinical studies are available.

Clinical Summary

MK-7 as a compound class has been studied in several randomized controlled trials; a notable 3-year RCT by Knapen et al. (2013, n=244 postmenopausal women) found that 180 mcg/day MK-7 significantly improved bone mineral density at the lumbar spine and femoral neck and reduced age-related vertebral bone strength loss. A 2015 RCT (n=60) demonstrated that MK-7 supplementation at 180 mcg/day significantly reduced undercarboxylated osteocalcin (ucOC) and improved carboxylated MGP levels, biomarkers of calcium regulation efficacy. MenaquinGold as a specific branded ingredient has published research focused primarily on its chickpea-based fermentation process, bioavailability profiling, and stability characteristics, with limited branded clinical outcome trials distinct from generic MK-7 research. Evidence for MK-7's bone and cardiovascular biomarker effects is moderately strong, though large-scale fracture-endpoint or cardiovascular event trials remain limited.

Nutritional Profile

MenaquinGold is a standardized, commercially produced Vitamin K2 as Menaquinone-7 (MK-7) derived from fermentation of Bacillus subtilis natto. Primary bioactive compound: MK-7 (all-trans menaquinone-7) at standardized concentrations typically ranging from 1,600–3,200 mcg/g of extract, depending on grade. MK-7 is a fat-soluble vitamin belonging to the K2 subclass characterized by a polyisoprenoid side chain of 7 isoprene units. Macronutrient contribution is negligible at typical supplemental doses (typically 45–200 mcg per serving). Key bioactive: all-trans MK-7 isomer, which is the biologically active configuration; trans isomer content in quality-grade MenaquinGold is typically >97% all-trans. Contains no meaningful fiber, protein, or mineral content at functional doses. Bioavailability: MK-7 has superior bioavailability compared to MK-4 and Vitamin K1 (phylloquinone) due to its long isoprenoid tail, which extends plasma half-life to approximately 72 hours versus 1–2 hours for K1. Absorption is enhanced when taken with dietary fat, consistent with all fat-soluble vitamins. Serum half-life allows once-daily dosing with sustained plasma levels. Requires bile salts for micellar solubilization and intestinal absorption via chylomicron incorporation. No significant mineral, carbohydrate, or caloric content at supplemental doses.

Preparation & Dosage

No clinically studied dosage ranges are reported in the available research. The literature emphasizes analytical and production processes without reference to human dosing. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Insufficient evidence to recommend synergistic ingredients

Safety & Interactions

Vitamin K2 MK-7 at standard supplemental doses of 90–360 mcg/day is generally well tolerated with no significant adverse effects reported in clinical trials lasting up to 3 years. The most clinically significant interaction is with warfarin (coumadin) and other vitamin K antagonist anticoagulants; MK-7's long half-life can meaningfully reduce anticoagulant efficacy, necessitating INR monitoring and medical supervision before co-administration. Individuals taking anticoagulants such as apixaban or rivaroxaban face lower but non-zero interaction risk, and those on bisphosphonates or mineral-binding medications should space supplementation by at least 2 hours. Pregnancy and lactation safety data are limited; while dietary vitamin K2 is considered safe, supplemental doses should be used under medical guidance during pregnancy.